Psoriasis pathophysiology presents significant barriers to effective treatment, primarily due to the thickened epidermis which severely limits transdermal drug delivery. Moreover, the hypoxic conditions prevalent in psoriatic lesions contribute to an inflammatory milieu that undermines the effectiveness of conventional therapies, including photodynamic therapy (PDT). The introduction of this dual-section microneedle (MN) patch, termed S-PTP MN patch, systematically addresses these obstacles by integrating oxygen generation capabilities and ROS-responsive drug release into a singular, patient-friendly device capable of penetrating deep into the affected dermal layers.

The needle section of the S-PTP MN patch is meticulously engineered with PTP nanoparticles loaded with the corticosteroid triamcinolone acetonide (TA), a cornerstone anti-inflammatory medication in dermatology. These particles are enveloped within a reactive oxygen species (ROS)-responsive layer, enabling the drug to be released precisely in the oxidative microenvironment characteristic of psoriatic lesions. This targeted, stimulus-responsive mechanism provides a controlled and sustained release of TA over six days, ensuring continuous therapeutic activity while minimizing systemic exposure and associated side effects.

Complementing the active drug delivery, the base section of the patch incorporates sodium percarbonate (SPC) particles, a strategic inclusion that serves as an oxygen generator. Upon application, the SPC particles react to release oxygen locally within the hypoxic microenvironment of the psoriatic skin. The resultant oxygenation not only facilitates deeper penetration of the PTP nanoparticles but also significantly enhances the efficacy of photodynamic therapy, which is inherently oxygen-dependent. This dual-action platform therefore optimizes both drug delivery and PDT in a synergistic manner.

An in-depth investigation utilizing an imiquimod-induced psoriatic mouse model demonstrated compelling therapeutic outcomes following a single application of the S-PTP MN patch. Compared to conventional topical TA cream, the microneedle patch achieved superior results in attenuating clinical symptoms of psoriasis. Quantitative analyses revealed marked reductions in epidermal thickness and a pronounced decrease in pro-inflammatory cytokine expression, underscoring the patch’s potent anti-inflammatory effect and its capacity to modulate the psoriatic immune response effectively.

The technological innovation reflected in this work revolves around the integration of stimuli-responsive drug release with oxygen generation—a pioneering approach that mitigates the traditional limitations of topical psoriasis treatments. The ROS-responsive coating acts as a molecular trigger, ensuring drug liberation selectively in the disease microenvironment, thereby sparing healthy tissues. Meanwhile, the oxygen supply mitigates hypoxia-induced resistance, addressing a significant hurdle in achieving sustained therapeutic responses in psoriasis management.

Furthermore, the sustained release profile of triamcinolone acetonide from the PTP nanoparticles is a critical advancement that not only prolongs drug efficacy but also improves patient compliance by reducing the need for frequent applications. This temporal control over drug dosing aligns well with the chronic nature of psoriasis, providing a consistent anti-inflammatory effect that can mitigate flare-ups and maintain disease remission more effectively than conventional formulations.

The microneedle patch design itself offers tangible benefits in terms of patient comfort and usability. By circumventing the stratum corneum barrier through minimally invasive penetration, the patch ensures localized delivery directly to the epidermal and dermal layers where psoriatic pathology is active. This localized administration theoretically reduces systemic drug exposure and minimizes side effects commonly associated with systemic corticosteroid therapies, such as adrenal suppression or skin atrophy.

This innovative platform also holds potential to revolutionize photodynamic therapy for psoriasis. PDT efficacy is greatly contingent upon oxygen availability, an attribute severely compromised in psoriatic tissues due to chronic inflammation and vascular alterations. The localized oxygen release of the S-PTP MN patch effectively reoxygenates the lesion microenvironment, not only augmenting the photochemical reactions central to PDT but also promoting cellular repair mechanisms and further attenuating inflammatory cascades in psoriatic plaques.

The implications of this study extend beyond the immediate clinical benefits for psoriasis patients, representing a versatile strategy for enhancing transdermal drug delivery in other conditions characterized by thickened or impaired skin barriers and hypoxic environments. The dual-section microneedle array, combining responsive drug delivery with in situ oxygen generation, establishes a novel design paradigm that could be adapted for the treatment of diverse chronic inflammatory and ischemic skin disorders.

Moreover, the formulation’s demonstrated efficacy in preclinical models sets the stage for translational research aimed at human clinical trials. Considering the global burden of psoriasis and the limitations of current therapies, the S-PTP MN patch offers a promising, scalable approach that could substantially improve quality of life for patients while alleviating the healthcare costs associated with chronic disease management.

Finally, this study underscores the value of multidisciplinary collaboration, integrating materials science, pharmacology, and dermatology to develop cutting-edge solutions for complex diseases. The synergy between nanotechnology, responsive biomaterials, and targeted therapy heralds a future where personalized, on-demand treatments become the standard of care in dermatological practice and beyond.

Subject of Research: Advanced drug delivery systems for psoriasis treatment

Article Title: Oxygen-boosted dual-section microneedle patch for enhanced drug penetration and improved photodynamic and anti-inflammatory therapy in psoriasis

News Publication Date: 2025

Web References:

• Acta Pharmaceutica Sinica B: https://www.sciencedirect.com/journal/acta-pharmaceutica-sinica-b
• DOI: http://dx.doi.org/10.1016/j.apsb.2025.09.037

Keywords: Psoriasis, Microneedle, Responsive release, Drug delivery, Oxygen, Reactive oxygen species, Sustained release, Triamcinolone acetonide

Psoriasis has long challenged scientists and clinicians alike due to its complex etiology, involving intricate interactions between immune system components, skin barrier functions, and genetic predispositions. Despite the availability of multiple treatments, many patients continue to endure relapses and incomplete responses to therapy. Recognizing this unmet clinical need, Chen and colleagues sought to dissect the psoriasis microenvironment with unprecedented granularity. By leveraging single-cell RNA sequencing (scRNA-seq) in human psoriatic skin samples alongside genetically engineered mouse models, the team achieved a nuanced cellular map of disease-associated changes.

At the heart of this investigation lies the intracellular enzyme Ube2l3, an E2 ubiquitin-conjugating enzyme previously implicated in immune regulation but not thoroughly examined in psoriasis. The researchers engineered mice with targeted deletion of Ube2l3 restricted to epidermal cells, providing an innovative model to evaluate the enzyme’s specific contributions within the skin milieu. These Ube2l3-deficient mice developed psoriasis-like phenotypes, confirming a pivotal role in disease onset and progression, and serving as a powerful experimental counterpart to the human data.

Single-cell transcriptomic analysis revealed that the lack of Ube2l3 in the epidermis leads to the aberrant expression of chemokines, key signaling molecules that recruit immune cells. Among these, CXCL16 emerged strikingly upregulated, acting as a beacon for immune cell infiltration. Correspondingly, the chemokine receptor CXCR6 demonstrated enhanced expression on immune cells that populate psoriatic lesions, suggesting a functional communication axis that perpetuates skin inflammation. This previously underappreciated CXCL16/CXCR6 signaling pathway was shown to be a critical driver in maintaining the chronic inflammatory loop characteristic of psoriasis.

The mechanistic insights gained from these detailed analyses reveal that the loss of Ube2l3 disrupts the ubiquitination landscape within keratinocytes, the predominant epidermal cells, thereby affecting downstream gene regulatory networks governing chemokine production. Through this molecular cascade, excessive CXCL16 secretion recruits CXCR6-positive immune subsets, including T cells, which amplify the inflammatory response. This discovery not only pinpoints a new molecular culprit in psoriasis but also introduces the CXCL16/CXCR6 axis as a viable target for drug development.

Importantly, the integration of human psoriasis scRNA-seq data with murine genetic models allowed the authors to validate their findings across species, enhancing the translational relevance of their conclusions. This cross-species approach underscores the power of comparative transcriptomics in dissecting complex diseases and avoiding pitfalls inherent in singular model systems. It also strengthens the argument for targeting chemokine pathways as potential therapeutic avenues.

Beyond elucidating epidermal-immune interactions, the study highlights the broader implications of ubiquitin-mediated signaling regulation in skin diseases. Given ubiquitination’s central role in protein turnover and signaling pathway modulation, the findings unravel how dysregulation at this fundamental level can tip the balance towards chronic inflammation. Such paradigm shifts may pave the way for reimagining other inflammatory and autoimmune disorders through a similar molecular lens.

Chen et al.’s work also contributes substantially to the growing appreciation of chemokine networks as critical modulators in inflammatory skin diseases. While classical psoriasis treatments have predominantly targeted cytokine pathways like TNF-α and IL-17, this research convincingly argues for expanding the therapeutic targets to include chemokine axes that govern immune cell trafficking. The CXCL16/CXCR6 pair, in particular, may serve as both diagnostic biomarkers and therapeutic targets, opening doors to personalized medicine approaches.

Moreover, the use of single-cell transcriptomics exemplifies the technological evolution that is transforming biomedical research. This powerful methodology provides nuanced resolution of cellular heterogeneity and gene expression dynamics, unraveling complex biological systems at an unprecedented scale. The ability to trace cell lineage, activation states, and intercellular communication deepens our comprehension of disease pathophysiology and informs precision therapeutic strategies.

While these findings signify a major advancement, the authors acknowledge the need for further investigations into the potential side effects and safety profiles of targeting the CXCL16/CXCR6 axis. Understanding how such interventions may impact normal immune surveillance and skin homeostasis will be critical before clinical application. Nonetheless, the therapeutic promise highlighted by this study signals a hopeful future for patients grappling with psoriasis.

This study epitomizes how integrative, multidisciplinary research combining immunology, genetics, molecular biology, and advanced computational analyses can yield transformative insights. It sets the stage for the development of novel biologics or small molecules designed to modulate chemokine receptor signaling, potentially revolutionizing treatment paradigms for psoriasis and related inflammatory disorders.

In conclusion, by unraveling the molecular intricacies of psoriasis through single-cell transcriptomics and innovative mouse genetics, Chen et al. have illuminated the central role of the CXCL16/CXCR6 chemokine axis. Their comprehensive findings not only advance fundamental understanding but also chart a promising path toward more effective and targeted therapies. This landmark research propels the field forward, offering renewed hope for patients and clinicians confronting chronic skin inflammation.

As we anticipate the next chapters of research building upon these discoveries, the integration of molecular insights into clinical practice remains a paramount goal. This study exemplifies how modern scientific rigor paired with novel technologies can unravel complex diseases, ultimately translating into tangible benefits that improve lives and reshape healthcare landscapes worldwide.

Subject of Research:
Psoriasis pathogenesis and the role of epidermal Ube2l3 and the CXCL16/CXCR6 chemokine axis.

Article Title:
Single cell transcriptomics of human psoriasis and epidermal specific Ube2l3 deficient mice highlight CXCL16/CXCR6 involvement in psoriasis development.

Article References:
Chen, XY., Ye, LR., Fu, NC. et al. Single cell transcriptomics of human psoriasis and epidermal specific Ube2l3 deficient mice highlight CXCL16/CXCR6 involvement in psoriasis development.
Nat Commun 16, 9084 (2025). https://doi.org/10.1038/s41467-025-64106-6

Image Credits: AI Generated